TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jan 12, 2021 10:56 JST
Source:
NEC Corporation
NEC Releases 'WISE VISION Endoscopy' in Europe and Japan
- Contributing to early detection of colorectal cancer -
TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe. This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2). Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress the progression to cancer by detecting and removing lesions at the polyp stage during endoscopy procedures. However, polyps need to be found with the eye of an endoscopist, and are often difficult to detect because of their size and shape, causing approximately 24%(3) to be missed, thereby delaying detection.
NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue. NEC has now developed software that can automatically mark potential lesions based on the use of AI to learn from endoscopic images of more than 10,000 lesions, as well as learning from the observations of expert physicians(4). This software was developed by applying NEC's AI technologies, "NEC the WISE," and its face recognition technology, which is highly evaluated by the National Institute of Standards and Technology(5) in the United States.
Software features include the following:
1. Compatibility with the endoscopy systems of three leading companies and usability in any examination room
This software can be connected to endoscopes from three leading endoscope manufacturers(6). By simply connecting an existing endoscope to a monitor and terminal equipped with the software, users can start using it immediately. Moreover, since it is compatible with various endoscopes and easy to prepare, systems can be transferred within different rooms and used efficiently wherever there is an examination.
2. High visibility and flexible interface
The system marks the lesion candidates with a notification sound and marking. Notification sounds, volume, and marker colors can be customized at any time to the user's preference. The system can be operated intuitively with a high-visibility user interface, allowing users to smoothly proceed with examinations.
Going forward, as a company that creates social value, NEC aims to promote a healthy, and sustainable society, where individuals can thrive from the utilization of advanced IT technologies.
(1) According to statistics from the National Cancer Research Center Japan (Japanese text only)
https://ganjoho.jp/reg_stat/statistics/stat/summary.html
(2) According to United European Gastroenterology
https://ueg.eu/p/78#
(3) Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112(1):24-28
(4) Yamada M, Saito Y, Imaoka H,et al. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Sci Rep. 2019;9:14465
(5) NEC Face Recognition Technology Ranks First in NIST Accuracy Testing
https://www.nec.com/en/press/201910/global_20191003_01.html
(6) Connectivity and operations have been confirmed with the following endoscopes
- Olympus EVIS LUCERA ELITE Video System Center CV-290
- FUJIFILM ELUXEO video processor VP-7000
- PENTAX Medical OPTIVISTA EPK-i7010 video processor
Product name: WISE VISION Endoscopy
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at
https://www.nec.com
.
Source: NEC Corporation
Sectors: MedTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
July 17 2026 21:16 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
July 15 2026 21:53 JST
NEC drives digital transformation at Messer Gases in Brazil with Cisco advanced networking and security solutions
July 02 2026 14:00 JST
NEC Recognized as a Specialist in Gartner(R) Emerging Market Quadrant for Physical AI Services - Established Vendors
June 30 2026 21:47 JST
NEC Participates in NATO CCDCOE's Cyber Defense Exercise "Locked Shields 2026"
June 23 2026 23:13 JST
BAE Systems and NEC Sign MoU to Strengthen Japan's Active Cyber Defence
June 17 2026 12:10 JST
Report verifying the net carbon impact of NEC's agricultural solution, CropScope, published as part of the Net Carbon Impact initiative promoted by the EU Green Digital Coalition
June 12 2026 20:40 JST
NEC's Face Recognition Walkthrough Gate for JR East railways wins "Best of the Best" at the "Red Dot Design Award 2026"
June 12 2026 12:29 JST
NEC Wins at the Newsweek AI Impact Awards 2026
June 03 2026 23:09 JST
NEC and New York University Evaluate Economic Impact of Flood Protection Project Around the Island of Manhattan
May 27 2026 11:03 JST
More Press release >>
Latest Press Release
Toyota, Volvo Group and Daimler Truck AG sign binding agreement for Toyota to join cellcentric as equal shareholder
Jul 28, 2026 00:39 JST
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 27, 2026 23:50 JST
Launch of a proof-of-concept experiment for a next-generation distributed AI processing infrastructure aiming to realize the Watt-Bit vision
Jul 27, 2026 23:24 JST
Next-generation spectator experience at KYOJO CUP: AI selects and delivers "The moment you want to see" with ultra-low latency
Jul 27, 2026 22:40 JST
Sharp Acquires Vietnamese Corporation Engaged in Solar EPC And O&M Business as A Wholly Owned Subsidiary
Jul 27, 2026 22:02 JST
Collaboration Agreement announced by Sovereign Effects Partners to support GCAP
Jul 27, 2026 21:49 JST
Chunghwa Telecom, Fujitsu and 1Finity to accelerate All-Photonics Network deployment and advance quantum technologies in Taiwan through strategic partnership
Jul 27, 2026 21:08 JST
JCB and Fiuu Collaborate to Expand JCB Acceptance Across Southeast Asia
Jul 23, 2026 12:00 JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
More Latest Release >>